Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fixed-Oil Excipient Monographs: Development of USP Fixed-Oil Reference Standards
This article summarizes the development and modernization of the United States Pharmacopeia-National Formulary (USP-NF) fixed-oil excipient monographs. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 102-108

Appendix

Iodine Value



The formula to estimate the iodine value from the Fatty Acid Composition profile (15–17) is:

where

IVmixture = iodine value

PFA = percentage of a fatty acid determined from the Fatty Acid Composition (%)

MW(2I) = atomic weight of two iodine atoms that are theoretically added to one double bond, 253.81

Ndb = number of double bonds

MW(FA) = molecular weight of the fatty acid.

The calculated iodine values for oleic acid, linoleic acid, linolenic acid (each with purity < 99%) using the equation above are 89.9, 181.0, and 237.5, respectively.

Saponification Value

The formula to estimate the saponification value from the Fatty Acid Composition profile (15,17) is:




For triglycerides

where

SVmixture = saponification value

PFA = percentage of a fatty acid determined from the Fatty Acid Composition (%)

MW(KOH)= molecular weight of potassium hydroxide, 56.11

MW(FA) = molecular weight of the fatty acid

MW(Glycerin) = molecular weight of glycerin, 92.09

MW(H2O) = molecular weight of water, 18.02.

About the Authors

Hong Wang* is senior scientific liaison at USP, Rockville, MD, hw@usp.org. Catherine Sheehan is director, excipients, USP. Lawrence H. Block (chair), Richard C. Moreton (vice-chair), Richard H. Wendt, Shireesh P. Apte, and Eric J. Munson are members of the USP 2010–2015 Monographs—Excipients Expert Committee.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here